Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies

J Zhang, Y Zhang, J Wang, Y Xia, J Zhang… - Signal transduction and …, 2024 - nature.com
Alzheimer's disease (AD) stands as the predominant form of dementia, presenting significant
and escalating global challenges. Its etiology is intricate and diverse, stemming from a …

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

X Xie, T Yu, X Li, N Zhang, LJ Foster, C Peng… - Signal transduction and …, 2023 - nature.com
Undruggable proteins are a class of proteins that are often characterized by large, complex
structures or functions that are difficult to interfere with using conventional drug design …

Evolution of cancer pharmacological treatments at the turn of the third millennium

L Falzone, S Salomone, M Libra - Frontiers in pharmacology, 2018 - frontiersin.org
The medical history of cancer began millennia ago. Historical findings of patients with
cancer date back to ancient Egyptian and Greek civilizations, where this disease was …

Polo-like kinase 1 inhibitors in human cancer therapy: development and therapeutic potential

J Zhang, L Zhang, J Wang, L Ouyang… - Journal of medicinal …, 2022 - ACS Publications
Polo-like kinase 1 (PLK1) plays an important role in a variety of cellular functions, including
the regulation of mitosis, DNA replication, autophagy, and the epithelial–mesenchymal …

Inhibitors of protein–protein interactions (PPIs): an analysis of scaffold choices and buried surface area

X Ran, JE Gestwicki - Current opinion in chemical biology, 2018 - Elsevier
Protein–protein interactions (PPI) were once considered 'undruggable', but clinical
successes, driven by advanced methods in drug discovery, have challenged that notion …

Cyclin-dependent kinase 2 inhibitors in cancer therapy: an update

S Tadesse, EC Caldon, W Tilley… - Journal of medicinal …, 2018 - ACS Publications
Cyclin-dependent kinase 2 (CDK2) drives the progression of cells into the S-and M-phases
of the cell cycle. CDK2 activity is largely dispensable for normal development, but it is …

[HTML][HTML] Gold nanoparticles as a drug delivery system for standard chemotherapeutics: A new lead for targeted pharmacological cancer treatments

M Yafout, A Ousaid, Y Khayati, IS El Otmani - Scientific African, 2021 - Elsevier
Despite the great progress in medical sciences, cancer is still a major health problem. Since
the majority of cancer treatment protocols include first-generation chemotherapeutic agents …

Inhibition of RNA-binding proteins with small molecules

P Wu - Nature Reviews Chemistry, 2020 - nature.com
Protein–RNA interactions have crucial roles in various cellular activities, which, when
dysregulated, can lead to a range of human diseases. The identification of small molecules …

[HTML][HTML] Progress with covalent small-molecule kinase inhibitors

Z Zhao, PE Bourne - Drug discovery today, 2018 - Elsevier
Highlights•Summarized the diverse types of warheads across the human
kinome.•Highlighted facile covalent reactive functional groups which bind protein …

New promise and opportunities for allosteric kinase inhibitors

X Lu, JB Smaill, K Ding - Angewandte Chemie International …, 2020 - Wiley Online Library
Drugs that function through allosteric inhibition of kinase signaling represent a promising
approach for the targeted discovery of therapeutics. The majority of developed allosteric …